Sugi Predict

Sugi Predict / Compounds / SCHEMBL981341

SCHEMBL981341

SCHEMBL981341

Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ ALDH1A1 P00352 2/20 0.71
▸ GAA P10253 2/20 0.71
▸ NPC1 O15118 2/20 0.71
▸ KDM4E B2RXH2 4/20 0.70
▸ RAB9A P51151 3/20 0.70
▸ POLB P06746 1/20 0.67
▸ NR1H4 Q96RI1 1/20 0.63
▸ PPARA Q07869 8/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ HSP90AA1 P07900 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ CRHBP P24387 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ CRHR2 Q13324 1/20 0.57
▸ PPARG P37231 2/20 0.55
▸ PPARD Q03181 2/20 0.55
▸ TARBP2 Q15633 1/20 0.55
▸ XDH P47989 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462657 0.88 ALDH1A1 (0.71) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL3825573 0.87 ALDH1A1 (0.74) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL3054846 0.87 GAA (0.74) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL15656353 0.87 ALDH1A1 (0.70) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL8339014 0.87 RAB9A (0.72) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL13407798 0.86 ALDH1A1 (0.81) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL8867441 0.85 SMN1; SMN2 (0.76) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL2168235 0.85 ALDH1A1 (0.70) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL14109466 0.85 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1GAANPC1KDM4E
SCHEMBL8338941 0.84 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1GAANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4829451-B2 — — 2011-12-07 — — JP claimed
US-20100137312-A1 NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-06-03 — — US claimed
EP-2148868-A1 NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2010-02-03 — — EP claimed
WO-2008138917-A1 NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-11-20 — — WO claimed
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression BOUILLOT ANNE (FR) 2004-07-29 — — US claimed
US-20040077654-A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-22 — — US claimed
EP-1351937-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 — — EP claimed
EP-1351936-A1 ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 — — EP claimed
US-6599918-B2 Inhibit Factor Xa Factor IIa (thrombin) AVENTIS PHARMACEUTICALS INC. 2003-07-29 — — US claimed
US-20020193410-A1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans AVENTIS PHARMACEUTICALS INC. 2002-12-19 — — US claimed
WO-2002055496-A1 ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 — — WO claimed
WO-2002055497-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 — — WO claimed
EP-1222182-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS Aventis Pharmaceuticals Inc. (US) 2002-07-17 — — EP claimed
WO-2001014358-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS AVENTIS PHARMACEUTICALS INC. (DE) 2001-03-01 — — WO claimed
CN-116375663-B Febuxostat hapten, artificial antigen and application thereof 华南农业大学 2024-06-14 — — CN disclosed
CN-113189842-B Preparation method of color filter 江苏穿越光电科技有限公司 2024-05-17 — — CN disclosed
CN-116375663-A Febuxostat hapten, artificial antigen and application thereof 华南农业大学 2023-07-04 — — CN disclosed
EP-0649410-A1 ANILIDE DERIVATIVES. GLAXO LAB SA (FR) 1995-04-26 — — EP disclosed
WO-1994001408-A1 ANILIDE DERIVATIVES LABORATOIRES GLAXO S.A. (FR) 1994-01-20 — — WO disclosed
EP-0513379-A1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LIMITED (JP) 1992-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137312-A1 NOVEL AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS KCNH1, KCNJ2, KCNN2 SMN1; SMN2 2653/4885ALDH1A1 824/4885GAA 2136/4885
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 SMN1; SMN2 4776/4885ALDH1A1 1002/4885GAA 4167/4885
US-20040077654-A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression LDLR, NR1H2, NCOR1 SMN1; SMN2 4612/4885ALDH1A1 947/4885GAA 1696/4885
US-20020193410-A1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans F2, TFPI, F3 SMN1; SMN2 2200/4885ALDH1A1 1396/4885GAA 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.